Table 1 Clinicopathological characteristics of PM/DM patients
| Â | Clinical manifestations | Muscle strength (MMT) | Muscle enzymes | Â | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Patients | Age (years) | Sex | Cutaneous involvement | Pulmonary involvement | Upper limbs | Lower limbs | CK (IU/L) | ALD (IU/L) | LDH (IU/L) | Therapy |
PM | P01 | 52 | F | – | IP | 4 | 4 | 1038 | 20.8 | 472 | PSL 30 mg/day CyA 150 mg/day |
P02 | 83 | F | – | – | 4 | 4 | 8359 | 90.4 | 1224 | PSL 40 mg/day TAC 2 mg/day | |
P03 | 45 | F | – | IP | 4 | 4 | 417 | 21.2 | 404 | PSL 40 mg/day TAC 3 mg/day IVCY 500 mg/4 weeks | |
P04 | 17 | F | – | – | 4 | 4 | 2737 | 37.4 | 448 | PSL 50 mg/day TAC 3 mg/day | |
P05 | 46 | M | – | – | 5 | 5 | 2451 | 17.6 | 497 | PSL 40 mg/day TAC 3 mg/day IVCY 500 mg/4 weeks | |
DM | D01 | 32 | F | H, G, E | IP | 4 | 3 | 6213 | 147 | 569 | PSL 50Â mg/day CyA 150Â mg/day |
D02 | 18 | F | E | – | 4 | 4 | 17,662 | 59.1 | 1349 | PSL 50 mg/day TAC 3 mg/day | |
D03 | 62 | M | H, G, E | – | 4 | 4 | 7026 | 54 | 955 | PSL 80 mg/day TAC 3 mg/day | |
D04 | 40 | F | G, E | IP | 4 | 4 | 4246 | 106.7 | 703 | PSL 50Â mg/day TAC 3Â mg/day | |
D05 | 65 | M | H, G, E | – | 5 | 5 | 1176 | 18.5 | 410 | PSL 60 mg/day IVCY 500 mg/4 weeks | |